BioDelivery Sciences International, Inc. revised earnings guidance for the full year 2021. For the year, the company expected Total Company Net Revenue to be in the range of $165 million to $167 million, compared to previous guidance of $162 million to $167 million.
BioDelivery Sciences International, Inc.
Equities
BDSI
US09060J1060
Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
+30.78% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.34% | 239B | |
+9.61% | 211B | |
-2.74% | 203B | |
+10.77% | 171B | |
+0.10% | 163B |